Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors

NCT02615054 · clinicaltrials.gov ↗

COMPLETED

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Trastuzumab Cardiotoxicity
HER2-Positive Breast Cancer Survivors

Interventions

DEVICE: 2D Echocardiogram
DEVICE: Cardiopulmonary exercise testing and post-CPET cardiac function

Sponsor

Memorial Sloan Kettering Cancer Center